These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 25716354)

  • 1. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.
    Wolfsgruber S; Jessen F; Koppara A; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Kornhuber J; Wagner M
    Neurology; 2015 Mar; 84(12):1261-8. PubMed ID: 25716354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
    Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
    Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study.
    Miebach L; Wolfsgruber S; Polcher A; Peters O; Menne F; Luther K; Incesoy E; Priller J; Spruth E; Altenstein S; Buerger K; Catak C; Janowitz D; Perneczky R; Utecht J; Laske C; Buchmann M; Schneider A; Fliessbach K; Kalbhen P; Heneka MT; Brosseron F; Spottke A; Roy N; Teipel SJ; Kilimann I; Wiltfang J; Bartels C; Düzel E; Dobisch L; Metzger C; Meiberth D; Ramirez A; Jessen F; Wagner M
    Alzheimers Res Ther; 2019 Jul; 11(1):66. PubMed ID: 31366409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
    J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
    Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
    Wagner M; Wolf S; Reischies FM; Daerr M; Wolfsgruber S; Jessen F; Popp J; Maier W; Hüll M; Frölich L; Hampel H; Perneczky R; Peters O; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Lewczuk P; Kornhuber J; Wiltfang J
    Neurology; 2012 Feb; 78(6):379-86. PubMed ID: 22238414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Sierra-Rio A; Balasa M; Olives J; Antonell A; Iranzo A; Castellví M; Bosch B; Grau-Rivera O; Fernandez-Villullas G; Rami L; Lladó A; Sánchez-Valle R; Molinuevo JL
    Neurodegener Dis; 2016; 16(1-2):69-76. PubMed ID: 26560503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
    Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
    J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study.
    Hessen E; Nordlund A; Stålhammar J; Eckerström M; Bjerke M; Eckerström C; Göthlin M; Fladby T; Reinvang I; Wallin A
    J Alzheimers Dis; 2015; 47(3):619-28. PubMed ID: 26401697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD.
    Bruno D; Gleason CE; Koscik RL; Pomara N; Zetterberg H; Blennow K; Johnson SC
    Int J Geriatr Psychiatry; 2019 Mar; 34(3):415-419. PubMed ID: 30430632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.